Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 9/20 | 0.51 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.44 |
| ▸ | CKS1B | P61024 | 1/20 | 0.42 |
| ▸ | SKP1 | P63208 | 1/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9608997 | 0.88 | TBK1 (0.45) | BTKTBK1CKS1BSKP1SKP2 | |
| SCHEMBL9607739 | 0.81 | TP53 (0.45) | TBK1 | |
| SCHEMBL9607736 | 0.79 | ADORA1 (0.51) | — | |
| SCHEMBL19283405 | 0.76 | IRAK4 (0.62) | BTK | |
| SCHEMBL15223282 | 0.72 | BTK (0.47) | BTKCKS1BSKP1SKP2KDM1A | |
| SCHEMBL15223285 | 0.72 | BTK (0.47) | BTKCKS1BSKP1SKP2KDM1A | |
| SCHEMBL31034555 | 0.72 | JAK1 (0.59) | BTKJAK1JAK2 | |
| SCHEMBL31124435 | 0.71 | BTK (0.46) | BTKJAK1CCRL2JAK2 | |
| SCHEMBL31124343 | 0.71 | BTK (0.46) | BTKJAK1CCRL2JAK2 | |
| SCHEMBL29070892 | 0.71 | BTK (0.41) | BTKTBK1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | F9, F8, F12 | BTK 94/4885TBK1 3883/4885CKS1B 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.